摘要
目的观察尤瑞克林治疗急性脑梗死的疗效及安全性。方法将106例急性脑梗死患者随机分为治疗组和对照组,对照组54例患者仅用基础用药,治疗组53例,除基础用药外,另用尤瑞克林0.15PNAU+0.9%氯化钠注射液100ml静脉滴注,1次/d,使用10～14d。评定患者治疗前后神经功能缺损程度(NIHSS)及残疾指数(mRSIndex),监测用药期间血压变化,检测肝、肾功能、纤维蛋白原、血小板、C反应蛋白,记录不良反应,并随访90dmRS。结果治疗后,两组患者NIHSS和mRS评分均降低(P<0.05),尤瑞克林治疗组NIHSS、mRS以及总有效率均优于对照组(P<0.05);治疗组90dmRS与治疗结束相比显著降低,与对照组90dmRS相比也显著降低(P<0.01)。结论尤瑞克林治疗急性脑梗死安全有效。
Objective To evaluate the efficacy andsafty of human urinary kallidinogenase in treating patientswith acute cerebral infarction.Methods 107 patients with acute cerebral infarction were randomly divided intotwo groups in this study.The control group were treated by Ginaton injection and aspirin and statin.The treatment group were given the basical drug treatment and urinary kallidinogenase.The national instiutes of Health StrokeScale（NIHSS）,mRS Index and therapeutic outcomes in the two groups were addessed before treatment and 14 daysafter initiating treatment.Results The NIHSS and mRS in the two groups were inproved after treatment,but those in the treatment group was incereased more dramatically,showing significant difference form those in control groups（P 〈0.05）.Curative effect of treatment group was better than that of control group（P 〈0.05）,the differenceeing significant.Conclusion Urinary kallidinogenase is efficacy and safty for acute cerebral infarction in improving the neurological deficits.
出处
《中国实用医药》
2011年第11期34-36,共3页
China Practical Medicine
关键词
尤瑞克林
急性脑梗死
治疗
Urinarykallid
Acute cerebral infarction
Treatment
